Antiemetic Emend's generic benefit after 15 yrs since origin

Acepharma succeeds in registering Atant

Listed at 59.5% of the original price, patients are less burdened with medication

Emend

As the generic of Emend will be applied starting this month, the burden of drug prices for patients is expected to decrease.

 

It is the first time in 15 years that generic for Emend capsule has been reimbursed since the original was listed.

 

According to industries on the 5th, Acepharma's Atant 80mg and Atant 125mg have been registered as benefits since the 1st of this month.

 

Emend of MSD Korea is used in combination with corticosteroids and 5-HT3 antagonists, and was registered in April 2007.

 

The 5-HT3 antagonist which ends with Setron is a popular drug.

 

The market size is also large, so generics have also come out a lot in 5-HT3 antagonists.

 

Aprepitant has not been released in the meantime, perhaps because of its strong partner drug nature, which is used in combination with 5-HT3 antagonists.

 

Of course, the market size is also smaller than the 5-HT3 antagonist.

 

Based on IQVIA, Emend's sales peaked at 6 billion won in 2019, followed by 5.2 billion won in 2020 and 4.8 billion won in 2021.

 

Acepharma started developing generic for Emend in 2018 and succeeded in obtaining the first generic license among domestic pharmaceutical companies in January.

 

And it was registered as of the 1st of this month.

 

As Emend's generic Attant is registered, the burden of drug prices for patients is also reduced.

 

Emend 80mg is listed at 11,044 won and Emend 125mg at 13,570 won.

 

Atant was listed at 59.5% of the original price due to the addition of First Generic, with a big difference of 6,571 won for 80mg and 8,074 won for 125mg.

 

Of course, the drug price is expected to be lowered to 70% before the addition of the original Emend is completed due to the registration of the generic.

 

Acepharma received a license for the drug import business in 2016 and received a total of four import items, including anticancer drugs.

 

The office is located in Munjeong-dong, Songpa-gu, Seoul.